作者 | 深水财经社 纳兰5月20日,港股医药板块因一则重磅消息而沸腾。三生制药在前一天晚上公告宣布,公司与跨国药企辉瑞就PD-1/VEGF双特异性抗体SSGJ-707达成总额超60亿美元的许可协议,折合人民币超过430亿,创下国产双抗药物License-out首付款纪录。这场交易不仅让三生制药股价单日飙涨近40%,市值一度突破500亿人民币,三天翻了一倍,更让国产双抗为代表的国产创新药行业再次...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.